| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CLL1; MICL; CD371; CLL-1; DCAL-2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CLEC12A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CLEC12A抗体的参考文献摘要示例：
---
1. **文献名称**: "CLEC12A is a myeloid-specific checkpoint molecule that mediates T cell suppression in AML"
**作者**: Bakker et al.
**摘要**: 研究揭示了CLEC12A在急性髓系白血病(AML)细胞中的高表达，并开发了一种靶向CLEC12A的单克隆抗体(mAb)。该抗体通过阻断CLEC12A的免疫抑制信号通路，增强T细胞对AML细胞的杀伤活性，在体外和小鼠模型中均显示出抗白血病效果。
---
2. **文献名称**: "Antibody-based targeting of CLEC12A in acute myeloid leukemia: a preclinical evaluation"
**作者**: Marshall et al.
**摘要**: 研究评估了一种人源化抗CLEC12A抗体(hCLEC12A-mAb)的治疗潜力。实验表明，该抗体可通过抗体依赖性细胞毒性(ADCC)和补体依赖性细胞毒性(CDC)特异性清除AML细胞，且在健康造血干细胞中无显著毒性，支持其作为AML靶向治疗的候选药物。
---
3. **文献名称**: "CLEC12A-directed CAR T cells for immunotherapy of acute myeloid leukemia"
**作者**: Alonso-Camino et al.
**摘要**: 研究构建了靶向CLEC12A的嵌合抗原受体T细胞(CAR-T)，并在体外和异种移植模型中验证其疗效。结果显示，CLEC12A-CAR-T能高效识别并清除AML细胞，同时避免对正常髓系前体细胞的过度损伤，为AML的免疫治疗提供了新策略。
---
注：以上文献为示例，实际引用时需核实具体来源及准确性。建议通过PubMed或Web of Science以关键词“CLEC12A antibody”或“CLEC12A immunotherapy”检索最新研究。
CLEC12A (C-type lectin domain family 12 member A), also known as MICL or DCAL-2. is a transmembrane protein belonging to the C-type lectin receptor (CLR) family. It is primarily expressed on myeloid cells, including monocytes, neutrophils, and dendritic cells, as well as on certain malignant cells, such as acute myeloid leukemia (AML) blasts. Structurally, CLEC12A contains an extracellular C-type lectin-like domain, a transmembrane region, and a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM). As an inhibitory receptor, it regulates immune responses by dampening activation signals, thereby maintaining immune homeostasis and preventing excessive inflammation.
CLEC12A antibodies target this receptor for both diagnostic and therapeutic purposes. In research, these antibodies are used to study CLEC12A's role in immune regulation, myeloid cell differentiation, and tumor immune evasion. Clinically, CLEC12A is considered a promising biomarker and therapeutic target in AML due to its high expression on leukemic cells and limited presence on healthy tissues. Antibody-based therapies, such as antibody-drug conjugates (ADCs) or CAR-T cell therapies, leverage CLEC12A antibodies to selectively eliminate malignant cells while sparing normal cells. Additionally, CLEC12A antibodies are employed in flow cytometry and immunohistochemistry to identify and characterize myeloid malignancies. Despite its immunosuppressive function in normal physiology, CLEC12A’s aberrant expression in cancers highlights its dual role as a regulator and a disease-associated antigen, driving ongoing research into its therapeutic potential.
×
